Threonine Requirement in Adult Males With Crohn's Disease Using IAAO
NCT04740541 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2025-05-30
Summary
The goal of the current study is to measure the requirement for threonine in patients with CD using the IAAO method and compare the requirement to previously determined threonine requirement estimated in young adults using the IAAO technique. It is hypothesize that the requirement for threonine in patients with CD will be higher than the threonine requirement previously determined in young adults using the IAAO method. Up to 10 clinically stable patients with CD will be recruited from the IBD Clinic at Mt. Sinai Hospital, Toronto, and subsequently followed up at the Clinical Research Center (CRC), The Hospital for Sick Children (SickKids), Toronto, Canada. Before the study begins, the participants will be required to visit the CRC (Room 5500 Hill Wing, The Hospital for Sick Children) for a pre-study assessment of their height, weight, fat mass, fat free mass, resting metabolic rate and medical history. These assessments will take about 3 hours to complete. They will need to have been fasted for 10 hours prior to the pre-study assessment. The pre-study assessment is needed to calculate their dietary requirements for the study, and to assess health status. After signing the consent form, the subjects will complete the screening procedures (height, weight, fasting blood sample and medical history questionnaire, BIA, Skinfold and calorimetry).
Each study will consist of a 2-day adaptation period to a prescribed diet in accordance with the energy requirement of the subject and 1-study day. The diet will provide an adequate amount of protein, of 1 g protein/kg/d. The 2-day adaptation period is to allow the body to adapt to an adequate amount of protein as it has been shown that protein kinetics is altered without it.
Dietary intakes during this time will be provided in the form of lactose-free milk shakes (Scandishake) with added carbohydrate (SolCarb) and protein (beneprotein) to meet the subjects' requirement.
Following the 2 days of adaptation is the study day where threonine intake will be randomly assigned and phenylalanine (Phe) kinetics will be measured with the use of isotopically labelled Phe. On this day, VCO2 will be measured by calorimetry immediately after the 5th meal for a period of 20 minutes.
On the study day (3rd day of each 3-day period), the diet will be provided as 8 hourly isocaloric, isonitrogenous meals made up of a flavored liquid formula and protein free cookies developed for use in amino acid kinetic studies. Each meal will represent 1/12th of the subject's total daily requirements. The nitrogen (protein) content of the diet will be provided in the form of a crystalline amino acid mixture based on the amino acid composition of egg protein.
* A daily multivitamin supplement will be provided during the study period.
* No other food or beverages will be consumed on the adaptation days except water, 1 cup clear tea, or 1 cup clear coffee.
* During the 8-hr study day, no other food or drink will be consumed except water.
* Urine and breath samples will be collected at baseline and at isotopic steady state.
* Breath samples will be collected simultaneously with urine samples.
* Five baseline breath samples will be collected 60, 45, 30, 15 min, and just before the tracer protocol begins.
* Three baseline urine samples will be collected 60, 30 min, and just before the tracer protocol begins.
* Four plateau breath samples will be collected every 15 minutes 2.5 h after the tracer protocol begins.
* Three plateau breath samples will be collected every 30 minutes 2.5 h after the tracer protocol begin
* Breath samples will be collected with subjects breathing into an Exetainers plastic tube and samples will be stored in pre-evacuated glass tubes at room temperature until analysis.
* Urine samples will be collected in Eppendorf tubes and stored at - 20 º C until analyzed for 1-13C phenylalanine enrichment.
* The rate of CO2 production (VCO2) will be measured on each testing day using a ventilated hood indirect calorimeter at meal 5 to quantify 13CO2 excretion in breath.
Subjects can choose to withdraw from the study at any time and for any reason, based on his/her individual judgment. In particular, if a subject is unable to tolerate the diet, whether it is regards to taste, loose stools or constipated stools, he/she has the right to withdraw at any time during the study.
Conditions
- Crohn Disease
- IBD
Interventions
- OTHER
-
Dietary Intakes (Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies)
Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies to meet nutritional requirements, 5 levels of threonine intakes
Sponsors & Collaborators
-
MOUNT SINAI HOSPITAL
collaborator OTHER -
The Hospital for Sick Children
lead OTHER
Principal Investigators
-
Glenda Courtney-Martin, PhD, RD · The Hospital for Sick Children
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 49 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-02-02
- Primary Completion
- 2027-08-30
- Completion
- 2027-08-30
Countries
- Canada
Study Locations
More Related Trials
-
Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease
NCT02704728 ·Status: COMPLETED ·Phase: NA
-
Immune Response Regulation and Nutritional Status of the Crohn's Disease Patients.
NCT01957423 ·Status: COMPLETED ·Phase: NA
-
Response Assessment in SB CD
NCT03646708 ·Status: ACTIVE_NOT_RECRUITING
-
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Combining Nutritional Therapy and Anti-TNFα Treatment in Pediatric Patients With Crohn's Disease
NCT07314606 ·Status: RECRUITING ·Phase: NA
-
Oral N-acetylglucosamine in Crohn's Disease
NCT07225998 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease
NCT05815355 ·Status: COMPLETED
-
The Impact of "Crohn's Disease-TReatment-with-EATing" Diet and Exclusive Enteral Nutrition on Healthy Gut Bacteria
NCT02426567 ·Status: COMPLETED ·Phase: NA
-
A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease
NCT04590508 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease
NCT02453607 ·Status: UNKNOWN
-
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.
NCT06432764 ·Status: COMPLETED ·Phase: PHASE1
-
Phenotyping of Adult Crohn's Focusing on Sarcopenia
NCT05572203 ·Status: UNKNOWN ·Phase: NA
-
Cytokines and Genes in Therapeutic Response in Crohn's Disease
NCT03266471 ·Status: COMPLETED
-
CP-461 for the Treatment of Crohn's Disease
NCT00042055 ·Status: COMPLETED ·Phase: PHASE2
-
Prebiotic Effect on Metabolites in Crohn's Disease
NCT01487759 ·Status: COMPLETED ·Phase: NA
-
Partial-enteral Nutrition Protocol for Crohn's Disease
NCT07113431 ·Status: COMPLETED ·Phase: NA
-
To Evaluate the Efficacy and Safety of Rapamycin for Crohn's Disease-related Stricture
NCT02675153 ·Status: UNKNOWN ·Phase: NA
-
Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study
NCT02450513 ·Status: COMPLETED
-
Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease
NCT00287170 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Intensive Post Exclusive Enteral Nutrition Study
NCT04225689 ·Status: UNKNOWN ·Phase: NA
-
Nutritional Status and Body Composition of Adult Patients With Crohn's Disease
NCT04915911 ·Status: UNKNOWN
-
Modeling Patient Response to a Therapeutic Diet in Crohn's Disease
NCT04596566 ·Status: UNKNOWN ·Phase: NA
-
Thalidomide in Treating Crohn's Disease
NCT02501291 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Glutamine on Intestinal Permeability in Crohn's Disease
NCT00838149 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Exclusion Diet for Crohn's Disease Plus Enteral Nutrition on Children and Adolescents With Crohn's Disease
NCT06353633 ·Status: NOT_YET_RECRUITING ·Phase: NA